Citadel Advisors
BDRX

Citadel Advisors’s Biodexa Pharmaceuticals BDRX Stock Holding History

Citadel Advisors’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27
Closed -$30K – 14249
2024
Q2 		$30K Buy
+27
New +$35.4K ﹤0.01% 12274
2022
Q1 		– Hold
0
– -$44K – 13570
2021
Q4 		– Hold
0
– – – 13313
2021
Q3 		– Hold
0
– -$54K – 13797
2021
Q2 		– Hold
0
– – – 13303
2021
Q1 		– Hold
0
– – – 10849
2020
Q4 		– Hold
0
– – – 10697
2019
Q1 		– Hold
0
– -$19K – 9252
2018
Q4 		– Hold
0
– – – 8763
2018
Q3 		– Hold
0
– – – 9064
2018
Q2 		– Hold
0
– – – 8658
2018
Q1 		– Hold
0
– – – 8169
2017
Q4 		– Hold
0
– -$18K – 7954
2017
Q3 		– Hold
0
– – – 7374

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Citadel Advisors's BDRX Position: Q3 2024 in Review

Citadel Advisors sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2024, closing a stake of 27 shares — an estimated $30K sold.

Citadel Advisors first reported a position in BDRX in Q2 2024 and held it in 1 quarter. The position peaked at $30K in Q2 2024. 5 funds tracked by Wall St. Rank hold BDRX as of Q3 2024.

  • Citadel Advisors reported no remaining Biodexa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 27 Biodexa Pharmaceuticals shares in Q3 2024, an estimated $30K.
  • Citadel Advisors first reported a position in Biodexa Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Citadel Advisors's Biodexa Pharmaceuticals position peaked at $30K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.